Overview
Stock Info
Quarterlies
New Releases
Events
Stay Updated
Corporate Presentation
Analyst Coverage
Palisade Bio is followed by the analysts listed here. Please note that any opinions, estimates or forecasts regarding Palisade Bio’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Palisade Bio or its management. Palisade Bio does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Company
Palisade Bio is a clinical-stage biopharmaceutical company advancing targeted oral therapies for inflammatory and fibrotic diseases. The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for targeted bioactivation in the ileum and colon, with the goal of improving pharmacology, tolerability and convenience for patients with inflammatory bowel disease.
Palisade Bio is now advancing towards two Phase 2 clinical studies in UC and Crohn’s disease (CD).